Optum in association with
Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

Lincolnshire *PACE Shorts*

Summary of PACEF decisions from November 2016

For further details see *PACE Bulletin* Volume 11 Number 1 (February 2017)

Device, Dressing or Drug	**Indication(s)**	**Traffic Light and *Joint Formulary* Status**
Galantamine modified release capsules (Consion XL) (Dr Reddy's Laboratories UK Ltd)	For the treatment of mild to moderate dementia in Alzheimer's disease	AMBER with shared care. Approved for inclusion in the *Lincolnshire Joint Formulary*. Preferred lower cost brand.
Galantamine sustained release capsules (*Galantex XL*) (Creo Pharma Ltd)	For the treatment of mild to moderate dementia in Alzheimer's disease	AMBER with shared care. Approved for inclusion in the *Lincolnshire Joint Formulary*. Preferred lower cost brand.
Galantamine sustained release capsules (*Gatalin XL*) (Aspire)	For the treatment of mild to moderate dementia in Alzheimer's disease	AMBER with shared care. Approved for inclusion in the *Lincolnshire Joint Formulary*. Preferred lower cost brand.
Galantamine sustained release capsules (*Gazylan XL*) (Teva UK Ltd)	For the treatment of mild to moderate dementia in Alzheimer's disease	AMBER with shared care. Approved for inclusion in the *Lincolnshire Joint Formulary*. Preferred lower cost brand.
Galantamine sustained release capsules (*Luventa XL*) (Fontus Health Ltd)	For the treatment of mild to moderate dementia in Alzheimer's disease	AMBER with shared care. Approved for inclusion in the *Lincolnshire Joint Formulary*. Preferred lower cost brand.
Memantine hydrochloride 10mg and 20mg orodispersible tablet *(Valios)*) (Dr Reddy's Laboratories UK Ltd)	For the treatment of moderate to severe Alzheimer's dementia.	AMBER with shared care. Approved for inclusion in the *Lincolnshire Joint Formulary*. Standard 10mg and 20mg tablets remain the preferred memantine formulation.
Metformin modified release tablets 500mg and 1 gram *(Sukkarto)* (Morningside)	For the treatment of type 2 diabetes mellitus in adult patients who are intolerant of standard release metformin and in whom prolonged release tablets allow the use of a dose not previously tolerated.	GREEN Approved for inclusion in the *Lincolnshire Joint Formulary*.
Rivastigmine transdermal patches 4.6mg/24hour, 9.5mg/24hour (*Alzest*) (Dr Reddy's Laboratories UK Ltd)	Licensed for the treatment of mild to moderate dementia in Alzheimer's disease	AMBER Specialist initiation; shared care guideline is required. Approved for inclusion in the *Lincolnshire Joint Formulary*. The use of the patch should be restricted to those for whom rivastigmine is considered an appropriate therapy and the patch an appropriate formulation.
Rivastigmine transdermal patches 4.6mg/24hour, 9.5mg/24hour	Licensed for the treatment of mild to moderate dementia in Alzheimer's disease	RED-RED Not approved for inclusion in the *Lincolnshire Joint Formulary*.

and 13.3mg/24 hour *(Erastig)* (Teva UK Ltd)		
Rivastigmine transdermal patches 4.6mg/24hour, 9.5mg/24hour and 13.3mg/24 hour (Exelon) (Novartis)	Licensed for the treatment of mild to moderate dementia in Alzheimer's disease or in Parkinson's disease	RED-RED 4.6mg/24hour, 9.5mg/24hour. Removed from the *Lincolnshire Joint Formulary* AMBER 13.3mg/24 hour Specialist initiation; shared care guideline is required. The use of the patch should be restricted to those for whom rivastigmine is considered an appropriate therapy and the patch an appropriate formulation. Remains of the *Lincolnshire Joint Formulary*.
Rivastigmine transdermal patches 4.6mg/24hour, 9.5mg/24hour (*Prometax*) (Novartis)	Licensed for the treatment of mild to moderate dementia in Alzheimer's disease	RED-RED Not approved for inclusion in the *Lincolnshire Joint Formulary*.
Rivastigmine transdermal patches 4.6mg/24hour, 9.5mg/24hour (*Voleze)* (Focus Pharmaceuticals)	Licensed for the treatment of mild to moderate dementia in Alzheimer's disease	RED-RED Not approved for inclusion in the *Lincolnshire Joint Formulary*.
Ropinirole modified release tablets 2mg, 3mg, 4mg, 6mg and 8mg *(Ipinnia XL)* (Ethypharm UK Ltd)	For use as monotherapy or as an adjunct to levodopa in Parkinson's disease.	AMBER without shared care. Approved for inclusion in the *Lincolnshire Joint Formulary*.
Ropinirole modified release tablets 2mg, 4mg, and 8mg *(Repinex XL)* (Aspire Pharma)	For use as monotherapy or as an adjunct to levodopa in Parkinson's disease.	AMBER without shared care. Included in the *Lincolnshire Joint Formulary*.
Ropinirole modified release tablets 2mg, 4mg, and 8mg *(Spiroco XL)* (Teva UK Ltd)	For use as monotherapy or as an adjunct to levodopa in Parkinson's disease.	AMBER without shared care. Included in the *Lincolnshire Joint Formulary*.
Venlafaxine modified release capsules 37.5mg, 75mg, 150mg *(VenlaBlue XL)* (Creo Pharma)	For major depression, generalised anxiety disorder and social anxiety disorder.	GREEN. Approved for inclusion in the *Lincolnshire Joint Formulary*.
Venlafaxine modified release capsules 75mg, 150mg, 225mg *(Vensir XL)* (Morningside)	For major depression, generalised anxiety disorder and social anxiety disorder.	GREEN. Approved for inclusion in the *Lincolnshire Joint Formulary*.

RED-RED: This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

RED: This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

AMBER: This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

GREEN: This signifies a product that is **approved for initiation in either primary or secondary care.**

What's new this month?

- ***Sukkarto* is a new lower cost sustained release tablet formulation of metformin and is approved for use in those intolerant to standard release metformin (see page 4).**
- **Venlafaxine should be prescribed as a low cost immediate release twice daily generic formulation wherever possible. Where a modified release product is required, a branded prescription for either *Venlablue XL* capsules or *Vensir XL* capsules should be issued (see page 5).**
- **The recommended starting dose of etoricoxib for the treatment of rheumatoid arthritis and ankylosing spondylitis has been reduced to 60 mg once daily, with the option to increase to a maximum of 90 mg once daily if necessary (see page 11).**
- **Some patients may have exacerbation or rebound symptoms of rosacea following initiation of treatment with brimonidine 3mg/g gel (*Mirvaso*). It is important to initiate treatment with a small amount of gel and increase the dose gradually, based on tolerability and treatment response (see page 12).**

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (http://lincolnshire-pacef.nhs.uk); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Cathy Johnson at cathy.johnson@nhs.net or catherine.johnson@optum.com

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at www.lincolnshirejointformulary.nhs.uk